nach oben

Erschienen in:

30.10.2021 | Recommendations

Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis

verfasst von: Hanan Al Rayes, Mansour Alazmi, Suzan Attar, Khaled Alderaan, Mushabab Alghamdi, Nayef Alghanim, Ahmed Alhazmi, Nadeer Alkhadhrawi, Mohammad Almohideb, Zeyad Alzahrani, Mohamed Bedaiwi, Hussein Halabi

Erschienen in: Rheumatology International | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Psoriatic arthritis (PsA) is a highly heterogeneous disease with complex manifestations. Limited understanding of the disease and non-availability of local guidelines pose challenges in the management of PsA in Saudi Arabia. Therefore, this expert consensus is aimed to provide recommendations on the management of patients with PsA, including referral pathway, definition of remission and treat-to-target (T2T) approach. A Delphi technique of consensus development was used involving an expert panel comprised of 10 rheumatologists, one dermatologist and one family physician. Based on the review of available published evidence and the opinions of clinical experts, key recommendations were developed. A consensus was achieved in defining the following: management guideline adaptable for Saudi Arabia, most useful screening tool, laboratory investigations, imaging tests and criteria for referring suspected PsA patients to a rheumatologist. In addition, an agreement was achieved in defining the T2T strategy and remission for the clinical management of PsA. Overall, these recommendations provide an evidence-based framework for the management of PsA patients in Saudi Arabia.

Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41:545–568. https://doi.org/10.1016/j.rdc.2015.07.001CrossRefPubMedPubMedCentral

Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957–970. https://doi.org/10.1056/NEJMra1505557CrossRefPubMed

Stolwijk C, van Onna M, Boonen A, van Tubergen A (2016) Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken) 68:1320–1331. https://doi.org/10.1002/acr.22831CrossRef

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al (2019) Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 80:251-265.e19. https://doi.org/10.1016/j.jaad.2018.06.027CrossRefPubMed

Gladman DD (2015) Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am 41:569–579. https://doi.org/10.1016/j.rdc.2015.07.003CrossRefPubMed

Liu J-T, Yeh H-M, Liu S-Y, Chen K-T (2014) Psoriatic arthritis: epidemiology, diagnosis, and treatment. World J Orthop 5:537–543. https://doi.org/10.5312/wjo.v5.i4.537CrossRefPubMedPubMedCentral

Gupta S, Syrimi Z, Hughes DM, Zhao SS (2021) Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 41:275–284. https://doi.org/10.1007/s00296-020-04775-2CrossRefPubMedPubMedCentral

Wu Y, Mills D, Bala M (2009) Impact of psoriasis on patients’ work and productivity: a retrospective, matched case-control analysis. Am J Clin Dermatol 10:407–410. https://doi.org/10.2165/11310440-000000000-00000CrossRefPubMed

Eder L, Gladman DD (2013) Psoriatic arthritis: phenotypic variance and nosology. Curr Rheumatol Rep 15:316. https://doi.org/10.1007/s11926-013-0316-4CrossRefPubMed

10.

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14-17. https://doi.org/10.1136/ard.2004.032482CrossRefPubMedPubMedCentral

11.

Haroon M, Gallagher P, FitzGerald O (2015) Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 74:1045–1050. https://doi.org/10.1136/annrheumdis-2013-204858CrossRefPubMed

12.

Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227. https://doi.org/10.1002/art.1780341003CrossRefPubMed

13.

Fournié B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V et al (1999) Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed 66:446–456PubMed

14.

Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78. https://doi.org/10.1016/0049-0172(73)90035-8CrossRefPubMed

15.

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673. https://doi.org/10.1002/art.21972CrossRefPubMed

16.

Tiwari V, Brent LH (2020) Psoriatic arthritis. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK547710. Accessed 10 Jul 2021

17.

Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA et al (2015) Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol 73:242–248. https://doi.org/10.1016/j.jaad.2015.05.001CrossRefPubMed

18.

Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I et al (2020) Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 79:778–786. https://doi.org/10.1136/annrheumdis-2020-217163CrossRefPubMed

19.

Kang EJ, Kavanaugh A (2015) Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis 6:194–203. https://doi.org/10.1177/2040622315582354CrossRefPubMedPubMedCentral

20.

Tucker LJ, Ye W, Coates LC (2018) Novel concepts in psoriatic arthritis management: can we treat to target? Curr Rheumatol Rep 20:71. https://doi.org/10.1007/s11926-018-0781-xCrossRefPubMedPubMedCentral

21.

Bedaiwi M, Al-Homood IA, El-Garf A, Uthman I, Sunna N, Nassier R et al (2019) Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East. Rheumatol Int 39:1321–1329. https://doi.org/10.1007/s00296-019-04319-3CrossRefPubMed

22.

National Institute for Health and Care Excellence (UK) (2017) Spondyloarthritis in over 16s: diagnosis and management. https://www.nice.org.uk/guidance/ng65. Accessed 10 Jul 2021

23.

Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700–712. https://doi.org/10.1136/annrheumdis-2020-217159CrossRefPubMed

24.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al (2019) Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken) 71:2–29. https://doi.org/10.1002/acr.23789CrossRef

25.

Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi survey technique. J Adv Nurs 32:1008–1015PubMed

26.

McMillan SS, King M, Tully MP (2016) How to use the nominal group and Delphi techniques. Int J Clin Pharm 38:655–662. https://doi.org/10.1007/s11096-016-0257-xCrossRefPubMedPubMedCentral

27.

National Institute for Health and Care Excellence (UK) (2012) Psoriasis: assessment and management. https://www.nice.org.uk/guidance/cg153 Accessed 10 Jul 2021

28.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW et al (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060–1071. https://doi.org/10.1002/art.39573CrossRefPubMed

29.

Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA (2007) The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 57:581–587. https://doi.org/10.1016/j.jaad.2007.04.001CrossRefPubMed

30.

Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS (2009) Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 27:469–474PubMed

31.

Gladman DD, Schentag CT, Tom BDM, Chandran V, Brockbank J, Rosen C, Farewell VT (2009) Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 68:497–501. https://doi.org/10.1136/ard.2008.089441CrossRefPubMed

32.

Khraishi M, Landells I, Mugford G (2010) The self-administered Psoriasis and Arthritis Screening Questionnaire (PASQ): a sensitive and specific tool for the diagnosis of early and established psoriatic arthritis. Psoriasis Forum 16a:9–16. https://doi.org/10.1177/247553031016a00202CrossRef

33.

Khraishi M, Mong J, Mugford G, Landells I (2011) The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients. J Cutan Med Surg 15:143–149. https://doi.org/10.2310/7750.2011.10018CrossRefPubMed

34.

Tinazzi I, Adami S, Zanolin EM, Caimmi C, Confente S, Girolomoni G et al (2012) The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford) 51:2058–2063. https://doi.org/10.1093/rheumatology/kes187CrossRef

35.

Audureau E, Roux F, Lons Danic D, Bagot M, Cantagrel A, Dernis E et al (2018) Psoriatic arthritis screening by the dermatologist: development and first validation of the “PURE-4 scale.” J Eur Acad Dermatol Venereol 32:1950–1953. https://doi.org/10.1111/jdv.14861CrossRefPubMed

36.

Salaffi F, Di Carlo M, Luchetti MM, Di Donato E, Campanati A, Benfaremo D et al (2018) A validation study of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol 36:127–135PubMed

37.

Punzi L, Podswiadek M, Oliviero F, Lonigro A, Modesti V, Ramonda R, Todesco S (2007) Laboratory findings in psoriatic arthritis. Reumatismo 59(Suppl 1):52–55. https://doi.org/10.4081/reumatismo.2007.1s.52CrossRefPubMed

38.

Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17–23. https://doi.org/10.1007/s10067-006-0214-5CrossRefPubMed

39.

Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N (2005) The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 44:1056–1060. https://doi.org/10.1093/rheumatology/keh686CrossRef

40.

Payet J, Goulvestre C, Bialé L, Avouac J, Wipff J, Job-Deslandre C et al (2014) Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J Rheumatol 41:2395–2402. https://doi.org/10.3899/jrheum.131375CrossRefPubMed

41.

FitzGerald O, Haroon M, Giles JT, Winchester R (2015) Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther 17:115. https://doi.org/10.1186/s13075-015-0640-3CrossRefPubMedPubMedCentral

42.

de Souza Bomtempo CA, da Cruz LR, Aparecida Ferreira G, Parreiras de Carvalho MA (2006) Clinical, laboratorial and radiographic evaluation in Brazilians with spondyloarthropaties. Rev Bras Reumatol 46:238–245. https://doi.org/10.1590/S0482-50042006000400002 (Article in Portuguese)CrossRef

43.

Elkayam O, Segal R, Caspi D (2004) Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis. Rheumatol Int 24:93–97. https://doi.org/10.1007/s00296-003-0325-0CrossRefPubMed

44.

Queiro R, Sarasqueta C, Belzunegui J, Gonzalez C, Figueroa M, Torre-Alonso JC (2002) Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum 31:413–418. https://doi.org/10.1053/sarh.2002.33470CrossRefPubMed

45.

D’Angelo S, Palazzi C, Gilio M, Leccese P, Padula A, Olivieri I (2016) Improvements in diagnostic tools for early detection of psoriatic arthritis. Expert Rev Clin Immunol 12:1209–1215. https://doi.org/10.1080/1744666X.2016.1193436CrossRefPubMed

46.

Dhir V, Aggarwal A (2013) Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol 44:141–148. https://doi.org/10.1007/s12016-012-8302-6CrossRefPubMed

47.

Poggenborg RP, Østergaard M, Terslev L (2015) Imaging in psoriatic arthritis. Rheum Dis Clin North Am 41:593–613. https://doi.org/10.1016/j.rdc.2015.07.007CrossRefPubMed

48.

Kaeley GS, Bakewell C, Deodhar A (2020) The importance of ultrasound in identifying and differentiating patients with early inflammatory arthritis: a narrative review. Arthritis Res Ther 22:1. https://doi.org/10.1186/s13075-019-2050-4CrossRefPubMedPubMedCentral

49.

Østergaard M, Eder L, Christiansen SN, Kaeley GS (2016) Imaging in the diagnosis and management of peripheral psoriatic arthritis—the clinical utility of magnetic resonance imaging and ultrasonography. Best Pract Res Clin Rheumatol 30:624–637. https://doi.org/10.1016/j.berh.2016.08.012CrossRefPubMed

50.

Ash ZR, Tinazzi I, Gallego CC, Kwok C, Wilson C, Goodfield M et al (2012) Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis 71:553–556. https://doi.org/10.1136/annrheumdis-2011-200478CrossRefPubMed

51.

Naredo E, Möller I, de Miguel E, Batlle-Gualda E, Acebes C, Brito E et al (2011) High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case–control study. Rheumatology (Oxford) 50:1838–1848. https://doi.org/10.1093/rheumatology/ker078CrossRef

52.

Wiell C, Szkudlarek M, Hasselquist M, Møller JM, Vestergaard A, Nørregaard J et al (2007) Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis. Arthritis Res Ther 9:R119. https://doi.org/10.1186/ar2327CrossRefPubMedPubMedCentral

53.

Poggenborg RP, Sørensen IJ, Pedersen SJ, Østergaard M (2015) Magnetic resonance imaging for diagnosing, monitoring and prognostication in psoriatic arthritis. Clin Exp Rheumatol 33:S66–S69PubMed

54.

Schoellnast H, Deutschmann HA, Hermann J, Schaffler GJ, Reittner P, Kammerhuber F et al (2006) Psoriatic arthritis and rheumatoid arthritis: findings in contrast-enhanced MRI. AJR Am J Roentgenol 187:351–357. https://doi.org/10.2214/AJR.04.1798CrossRefPubMed

55.

Schwenzer NF, Kötter I, Henes JC, Schraml C, Fritz J, Claussen CD, Horger M (2010) The role of dynamic contrast-enhanced MRI in the differential diagnosis of psoriatic and rheumatoid arthritis. AJR Am J Roentgenol 194:715–720. https://doi.org/10.2214/AJR.09.2671CrossRefPubMed

56.

McGonagle D, Hermann K-GA, Tan AL (2015) Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford) 54:29–38. https://doi.org/10.1093/rheumatology/keu328CrossRef

57.

Narváez J, Narváez JA, de Albert M, Gómez-Vaquero C, Nolla JM (2012) Can magnetic resonance imaging of the hand and wrist differentiate between rheumatoid arthritis and psoriatic arthritis in the early stages of the disease? Semin Arthritis Rheum 42:234–245. https://doi.org/10.1016/j.semarthrit.2012.03.016CrossRefPubMed

58.

Tan AL, Grainger AJ, Tanner SF, Emery P, McGonagle D (2006) A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum 54:1328–1333. https://doi.org/10.1002/art.21736CrossRefPubMed

59.

Coates LC, Hodgson R, Conaghan PG, Freeston JE (2012) MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol 26:805–822. https://doi.org/10.1016/j.berh.2012.09.004CrossRefPubMed

60.

Mandl P, Navarro-Compán V, Terslev L, Aegerter P, van Der Heijde D, D’Agostino M et al (2015) EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 74:1327–1339. https://doi.org/10.1136/annrheumdis-2014-206971CrossRefPubMed

61.

Koolaee RM, Takeshita J, Ogdie A (2013) Epidemiology and natural history of psoriatic arthritis: an update what dermatologists need to know. Curr Dermatol Rep 2:66–76. https://doi.org/10.1007/s13671-012-0032-8CrossRef

62.

Mease PJ, Garg A, Helliwell PS, Park JJ, Gladman DD (2014) Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting. J Rheumatol 41:1249–1251. https://doi.org/10.3899/jrheum.140182CrossRefPubMed

63.

Conaghan PG, Strand V, Deodhar A, Sullivan E, Blackburn S, Tian H et al (2017) ABS273 Appropriate psoriatic arthritis (PSA) treatment is delayed for years: multinational survey results including Asia Pacific (APAC) and Middle East (ME). Int J Rheumatic Dis 20:66. https://doi.org/10.1111/1756-185X.13178CrossRef

64.

Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O et al (2014) Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) 66:1759–1766. https://doi.org/10.1002/acr.22404CrossRef

65.

Taylor SL, Petrie M, O’Rourke KS, Feldman SR (2009) Rheumatologists’ recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients’ joint symptoms. J Dermatolog Treat 20:350–353. https://doi.org/10.3109/09546630902817887CrossRefPubMed

66.

Belinchón I, Salgado-Boquete L, López-Ferrer A, Ferran M, Coto-Segura P, Rivera R et al (2020) Dermatologists’ role in the early diagnosis of psoriatic arthritis: expert recommendations. Actas Dermo-Sifiliográficas (English Edition) 111:835–846. https://doi.org/10.1016/j.adengl.2020.10.025CrossRef

67.

Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD et al (2012) Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermosifiliogr 103:1–64. https://doi.org/10.1016/S0001-7310(12)70001-7 (Article in Spanish)CrossRefPubMed

68.

Favier G, Gladman DD, Merola JF, Armstrong AW, Boehncke WH, Helliwell PS (2017) Benchmarking care in psoriatic arthritis—the QUANTUM report: a report from the GRAPPA 2016 annual meeting. J Rheumatol 44:674–678. https://doi.org/10.3899/jrheum.170142CrossRefPubMed

69.

Boehncke WH, Qureshi A, Merola JF, Thaçi D, Krueger GG, Walsh J et al (2014) Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol 170:772–786. https://doi.org/10.1111/bjd.12748CrossRefPubMed

70.

Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y (2019) Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis. Semin Arthritis Rheum 49:381–388. https://doi.org/10.1016/j.semarthrit.2019.06.001CrossRefPubMed

71.

Ogdie A, Coates LC, Gladman DD (2020) Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford) 59:i37–i46. https://doi.org/10.1093/rheumatology/kez383CrossRef

72.

Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L (2014) Review: treat to target in rheumatoid arthritis: fact, fiction or hypothesis? Arthritis Rheumatol 66:775–782. https://doi.org/10.1002/art.38323CrossRefPubMedPubMedCentral

73.

Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386:2489–2498. https://doi.org/10.1016/S0140-6736(15)00347-5CrossRefPubMedPubMedCentral

74.

Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P et al (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:6–16. https://doi.org/10.1136/annrheumdis-2013-203419CrossRefPubMed

75.

Smolen JS, Schöls M, Braun J, Dougados M, Fitzgerald O, Gladman DD et al (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77:3–17. https://doi.org/10.1136/annrheumdis-2017-211734CrossRefPubMed

76.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H et al (2018) Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 70:345–355. https://doi.org/10.1002/art.40391CrossRefPubMed

77.

Dures E, Shepperd S, Mukherjee S, Robson J, Vlaev I, Walsh N, Coates LC (2020) Treat-to-target in PsA: methods and necessity. RMD Open 6:e001083. https://doi.org/10.1136/rmdopen-2019-001083CrossRefPubMedPubMedCentral

78.

Coates LC, Nash P, Kvien TK, Gossec L, Mease PJ, Rasouliyan L et al (2020) Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Semin Arthritis Rheum 50:709–718. https://doi.org/10.1016/j.semarthrit.2020.03.015CrossRefPubMed

79.

Dures E, Taylor J, Shepperd S, Mukherjee S, Robson J, Vlaev I et al (2020) Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis. Ann Rheum Dis 79:1031–1036. https://doi.org/10.1136/annrheumdis-2020-217301CrossRefPubMed

80.

Mease PJ, Coates LC (2018) Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 47:786–796. https://doi.org/10.1016/j.semarthrit.2017.10.021CrossRefPubMed

81.

Gladman DD, Hing EN, Schentag CT, Cook RJ (2001) Remission in psoriatic arthritis. J Rheumatol 28:1045–1048PubMed

82.

Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24:S83–S87. https://pubmed.ncbi.nlm.nih.gov/17083768

83.

Coates LC, FitzGerald O, Mease PJ, Gladman DD, Strand V, Goel N et al (2014) Development of a disease activity and responder index for psoriatic arthritis—report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol 41:782–791. https://doi.org/10.3899/jrheum.131250CrossRefPubMed

84.

Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48–53. https://doi.org/10.1136/ard.2008.102053CrossRefPubMed

85.

Coates LC, Helliwell PS (2016) Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 43:371–375. https://doi.org/10.3899/jrheum.150826CrossRefPubMed

86.

Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS (2010) Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69:1441–1447. https://doi.org/10.1136/ard.2009.122259CrossRefPubMed

87.

Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811–818. https://doi.org/10.1136/annrheumdis-2015-207507CrossRefPubMed

88.

Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A (2019) Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value. J Rheumatol 46:160–165. https://doi.org/10.3899/jrheum.180249CrossRefPubMed

89.

Lubrano E, Perrotta FM (2017) Psoriatic arthritis: is it time to treat-to-target or target to treat? Clin Rheumatol 36:2633–2635. https://doi.org/10.1007/s10067-017-3885-1CrossRefPubMed

90.

Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 43:350–355. https://doi.org/10.3899/jrheum.150805CrossRefPubMed

91.

Orbai A-M, de Wit M, Mease P, Shea JA, Gossec L, Leung YY et al (2017) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 76:673–680. https://doi.org/10.1136/annrheumdis-2016-210242CrossRefPubMed

Titel: Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis
verfasst von: Hanan Al Rayes
Mansour Alazmi
Suzan Attar
Khaled Alderaan
Mushabab Alghamdi
Nayef Alghanim
Ahmed Alhazmi
Nadeer Alkhadhrawi
Mohammad Almohideb
Zeyad Alzahrani
Mohamed Bedaiwi
Hussein Halabi
Publikationsdatum: 30.10.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 3/2022
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-05029-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination

Evaluation of Big Five personality factors in women with fibromyalgia: a cross-sectional study

Sacroiliac joint in sarcoidosis on computed tomography: a monocentric retrospective study (SISTER)

Outcomes of multisystem inflammatory syndrome in children temporally related to COVID-19: a longitudinal study

Takayasu arteritis in an adolescent with Crohn’s disease

High expression of pro-inflammatory cytokine genes IL-1β and IL-1R2 upon TLR4 activation in Takayasu arteritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin